Cadrenal Therapeutics (CVKD) Notes Payables (2022)
Cadrenal Therapeutics (CVKD) posted Notes Payables of $43728.0 for Q4 2022.
Cadrenal Therapeutics (CVKD) Notes Payables (2022) Analysis & Trends
Cadrenal Therapeutics has reported Notes Payables for 1 years, with the latest figure at $43728.0 in Q4 2022.
- Quarterly Notes Payables changed N/A year-over-year to $43728.0 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $43728.0 (changed N/A YoY) and the FY2022 annual result came in at $43728.0, changed N/A from the prior year.
- Notes Payables steadied at $43728.0 in Q4 2022 per CVKD's latest filing.
- Over five years, Notes Payables peaked at $43728.0 in Q4 2022 and troughed at $43728.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - |
| 10 | Cadrenal Therapeutics | 4.57 Mn | 2.17 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 43,728.00 |